Raymond Cohen Buys Shares of RxSight, Inc.

Raymond Cohen made a notable move by purchasing 30,864 shares of RxSight, Inc. (NasdaqGM: RXST) on June 17, 2026. This insider buying suggests confidence in the company's future prospects.

What Changed in Raymond Cohen's RxSight, Inc. Position

Raymond Cohen, whose role was not specified, acquired 30,864 shares of RxSight, Inc. on June 17, 2026. The details of the transaction, such as the price paid or the total value, were not disclosed. However, this acquisition indicates an increase in his stake in the company.

Other Institutional Activity in RxSight, Inc.

Several institutional investors have also made changes to their positions in RxSight, Inc. BlackRock, Inc. increased its holdings by 482,086 shares, bringing its total to 3,187,092 shares, valued at approximately $19.6 million. Millennium Management LLC and Artisan Partners Limited Partnership reduced their stakes by 69,579 and 98,580 shares, respectively, with remaining holdings of 2,059,459 and 2,058,684 shares. Nomura Holdings Inc. maintained its position, holding steady at 2,000,060 shares worth about $12.3 million. Meanwhile, D. E. Shaw & Co., Inc. added 75,903 shares, ending with 1,959,732 shares valued at $12.1 million.

RxSight, Inc. Stock Snapshot

Shares of RxSight, Inc. were trading at $4.73. The company has a market capitalization of $195.8 million and does not have a meaningful P/E ratio as it is not currently profitable. The stock's 52-week range is between $4.48 and $14.29, with a 50-day moving average of $6.09 and a 200-day moving average of $8.36. The beta is 1.134, indicating moderate volatility compared to the market.

Recent Earnings

RxSight, Inc. reported revenue of $127.5 million, although it experienced a decline with a revenue growth rate of -18.5%. The company posted a net margin of -36.6% and a return on equity of -17.1%. The next earnings release is scheduled for August 6, 2026.

Insider Buying and Selling at RxSight, Inc.

On June 17, 2026, several insiders, including Juliet Tammenoms Bakker, Robert Keith Warner, Robert Palmisano, William Link, PhD, Shweta Maniar, and Jesse Anderson Corley, each purchased 37,037 shares of RxSight, Inc. These transactions were not part of planned trading programs.

Analysts Set New Price Targets

On May 7, 2026, Wells Fargo maintained a 'hold' rating with a price target of $9.00, while Needham continued with a 'buy' rating, setting a target at $11.00. The consensus among seven analysts is a target mean price of $8.79.

About RxSight, Inc.

RxSight, Inc., based in Aliso Viejo, California, is a medical technology company specializing in light adjustable intraocular lenses used in cataract surgery. The company offers the RxSight system, which includes the Light Adjustable Lens and a light delivery device, allowing doctors to enhance patients' visual acuity post-surgery. Led by CEO Dr. Ronald M. Kurtz, RxSight employs 461 people and operates within the healthcare sector, focusing on medical devices.

Bottom Line

Raymond Cohen's recent purchase of RxSight shares adds to the company's insider activity, which could signal confidence in its future. Investors often watch insider transactions for potential insights. As a reminder, insider trading reports are filed after the trades occur and may not reflect current positions.